These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24139069)

  • 1. Synchronous and metachronous metastatic breast cancer--two incarnations of the same beast?
    Senkus E
    Breast; 2014 Feb; 23(1):1. PubMed ID: 24139069
    [No Abstract]   [Full Text] [Related]  

  • 2. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease.
    Heron DE; Komarnicky LT; Hyslop T; Schwartz GF; Mansfield CM
    Cancer; 2000 Jun; 88(12):2739-50. PubMed ID: 10870056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor characteristics of the second tumor in synchronous versus metachronous breast cancer.
    Bu-Ali H; Solh M; Kapur A; Mittal V
    Am Surg; 2008 Aug; 74(8):702-5; discussion 706. PubMed ID: 18705570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bilateral primary breast cancers: a clinicopathological study of the second primary.
    Awad AT; el-Husseini G; Anwar M; Abu-Nasr A; Anwar AA; Sakr M
    Int Surg; 1996; 81(1):57-60. PubMed ID: 8803708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity of drug resistance in human breast and ovarian cancers.
    Kern DH
    Cancer J Sci Am; 1998; 4(1):41-5. PubMed ID: 9467045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bilateral breast carcinoma. 12 years' experience].
    Maculotti L; Gandini F; Pradella P
    Minerva Chir; 1996; 51(1-2):33-7. PubMed ID: 8677043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilateral synchronous breast cancer developed as metachronous malignancy after therapy of other primaries.
    Kurzyński M; Mituś J; Kołodziej-Rzepa M; Sas-Korczyńska B
    Ginekol Pol; 2018; 89(5):235-239. PubMed ID: 30084474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours.
    Carmichael AR; Bendall S; Lockerbie L; Prescott R; Bates T
    Eur J Surg Oncol; 2002 Jun; 28(4):388-91. PubMed ID: 12099647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Women with multiple primary breast cancers diagnosed within a five year period, 1994-1998.
    Howe HL; Weinstein R; Alvi R; Kohler B; Ellison JH
    Breast Cancer Res Treat; 2005 Apr; 90(3):223-32. PubMed ID: 15830135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bilateral carcinoma of the breast].
    Napolitano L; Grossi S; Cianchetti E
    Ann Ital Chir; 1993; 64(6):665-8; discussion 668-9. PubMed ID: 8080156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synchronous and metachronous malignant tumours expect the unexpected.
    Mehdi I; Shah AH; Moona MS; Verma K; Abussa A; Elramih R; El-Hashmi H
    J Pak Med Assoc; 2010 Nov; 60(11):905-9. PubMed ID: 21375191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer.
    Sandberg ME; Hartman M; Klevebring D; Eloranta S; Ploner A; Hall P; Czene K
    Breast Cancer Res Treat; 2012 Jul; 134(2):793-800. PubMed ID: 22622811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multiple primary colorectal cancer: Clinical aspects].
    Soldatkina NV; Kit OI; Gevorkyan YA; Milakin AG
    Ter Arkh; 2016; 88(8):53-58. PubMed ID: 27636928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Multiple primary breast cancer].
    Volchenko NN
    Arkh Patol; 1999; 61(4):21-5. PubMed ID: 10520424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of synchronous and metachronous multiple colorectal cancers.
    Ikeda Y; Saku M; Kawanaka H; Muranaka T; Takeshita M; Watanabe J; Yoshida K; Sugimachi K
    Hepatogastroenterology; 2004; 51(56):443-6. PubMed ID: 15086178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bilateral breast carcinoma: clinical characteristics and its impact on survival.
    Vuoto HD; García AM; Candás GB; Zimmermann AG; Uriburu JL; Isetta JA; Cogorno L; Khoury M; Bernabó OL
    Breast J; 2010; 16(6):625-32. PubMed ID: 21070440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Will modern immunotherapies become the standard of care for advanced synchronous or metachronous cancers?
    Kourie HR; Awada AH
    Future Oncol; 2015 Nov; 11(22):3053-5. PubMed ID: 26436764
    [No Abstract]   [Full Text] [Related]  

  • 18. Bilateral breast cancer: differential diagnosis using histological and biological parameters.
    Gong SJ; Rha SY; Jeung HC; Roh JK; Yang WI; Chung HC
    Jpn J Clin Oncol; 2007 Jul; 37(7):487-92. PubMed ID: 17673471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The incidence of bilateral multiple primary breast cancer among the female inhabitants of Crimea].
    Tel'kina GN; Sorkin VM
    Lik Sprava; 1998 Aug; (6):143-5. PubMed ID: 9844902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contralateral breast cancer: factors associated with stage and size at presentation.
    Mertens WC; Hilbert V; Makari-Judson G
    Breast J; 2004; 10(4):304-12. PubMed ID: 15239788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.